Earnings Per Share (GAAP)
$1.23
vs $-0.43 est.
Revenue
$1.1M
vs $3.2M est.
Massive EPS surprise. Curis, Inc. (NASDAQ: CRIS) reported Q4 2025 GAAP EPS of $1.23 versus the consensus estimate of -$0.43, beating by 384.4%. The biotechnology company swung to profitability with net income of $19.4 million, a sharp reversal from the year-ago loss. Four analysts covered the quarter, with estimates ranging from -$0.72 to -$0.28 per share. The stock traded at $0.89, up from its 52-week low of $0.77 but well below the $3.13 high.
Revenue falls short. Q4 revenue of $1.1 million missed the $3.2 million consensus, falling short by 66%. Revenue declined 67% year-over-year from $3.3 million in Q4 2024. The sharp revenue contraction stands in stark contrast to the profitability surprise, suggesting the EPS beat was driven by non-operating items rather than core business momentum. Trading volume reached 138,507 shares on the report date.
What to Watch: Review the earnings call transcript and press release for details on the $19.4 million net income source—asset sales, licensing deals, or restructuring gains will determine if this profitability is repeatable or a one-quarter anomaly.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
